Cover Image
市場調查報告書

ArisGen SA- 產品平台檢討

ArisGen SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 331739
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
ArisGen SA- 產品平台檢討 ArisGen SA - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 23 Pages
簡介

ArisGen SA是總公司設在瑞士的研究導向製藥企業。有肽醫藥品、代謝疾病與腫瘤的治療相關產品等。製造、生產、銷售,加上專利的劑型技術、肽治療藥的遞送、臨床開發的組合。

本報告提供ArisGen SA的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

ArisGen SA的基本資料

  • ArisGen SA概要
  • 主要資訊
  • 企業資料

ArisGen SA:R&D概要

  • 主要的治療範圍

ArisGen SA:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

ArisGen SA:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

ArisGen SA:藥物簡介

  • exenatide
  • leuprolide acetate
  • MIF-1
  • octreotide acetate
  • parathyroid hormone
  • insulin human

ArisGen SA:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ArisGen SA:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC07019CDB

Summary

Global Markets Direct's, 'ArisGen SA - Product Pipeline Review - 2015', provides an overview of the ArisGen SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ArisGen SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ArisGen SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ArisGen SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ArisGen SA's pipeline products

Reasons to buy

  • Evaluate ArisGen SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ArisGen SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ArisGen SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ArisGen SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ArisGen SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ArisGen SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ArisGen SA Snapshot
    • ArisGen SA Overview
    • Key Information
    • Key Facts
  • ArisGen SA - Research and Development Overview
    • Key Therapeutic Areas
  • ArisGen SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ArisGen SA - Pipeline Products Glance
    • ArisGen SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ArisGen SA - Drug Profiles
    • exenatide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leuprolide acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIF-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • octreotide acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • parathyroid hormone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • insulin human
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ArisGen SA - Pipeline Analysis
  • ArisGen SA - Pipeline Products by Target
  • ArisGen SA - Pipeline Products by Route of Administration
  • ArisGen SA - Pipeline Products by Molecule Type
  • ArisGen SA - Pipeline Products by Mechanism of Action
  • ArisGen SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ArisGen SA, Key Information
  • ArisGen SA, Key Facts
  • ArisGen SA - Pipeline by Indication, 2015
  • ArisGen SA - Pipeline by Stage of Development, 2015
  • ArisGen SA - Monotherapy Products in Pipeline, 2015
  • ArisGen SA - Preclinical, 2015
  • ArisGen SA - Discovery, 2015
  • ArisGen SA - Pipeline by Target, 2015
  • ArisGen SA - Pipeline by Route of Administration, 2015
  • ArisGen SA - Pipeline by Molecule Type, 2015
  • ArisGen SA - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • ArisGen SA - Pipeline by Top 10 Indication, 2015
  • ArisGen SA - Pipeline by Stage of Development, 2015
  • ArisGen SA - Monotherapy Products in Pipeline, 2015
  • ArisGen SA - Pipeline by Top 10 Target, 2015
  • ArisGen SA - Pipeline by Top 10 Route of Administration, 2015
  • ArisGen SA - Pipeline by Top 10 Molecule Type, 2015
  • ArisGen SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top